Galileo A Gonzalez-Conchas1, Laura Rodriguez-Romo2, David Hernandez-Barajas1, Juan F Gonzalez-Guerrero1, Ivan A Rodriguez-Fernandez1, Adrian Verdines-Perez1, Arnoud J Templeton3, Alberto Ocana4, Bostjan Seruga5, Ian F Tannock6, Eitan Amir6, Francisco E Vera-Badillo7. 1. Centro Universitario Contra el Cáncer, Hospital Universitario, Universidad Autónoma de Nuevo León, Monterrey, Mexico. 2. Centro Universitario Contra el Cáncer, Hospital Universitario, Universidad Autónoma de Nuevo León, Monterrey, Mexico; Canadian Cancer Trials Group, Department of Medical Oncology, Faculty of Medicine, Queen's University, Kingston, Ontario, Canada. 3. Department of Medical Oncology, St Claraspital and Faculty of Medicine, University of Basel, Basel, Switzerland. 4. Medical Oncology Department and Translational Research Unit, Albacete University Hospital, Albacete, Spain. 5. Sector of Medical Oncology, Institute of Oncology Ljubljana, Ljubljana, Slovenia. 6. Division of Medical Oncology & Hematology, Princess Margaret Cancer Centre, Department of Medicine, University of Toronto, Toronto, Canada. 7. Centro Universitario Contra el Cáncer, Hospital Universitario, Universidad Autónoma de Nuevo León, Monterrey, Mexico; Canadian Cancer Trials Group, Department of Medical Oncology, Faculty of Medicine, Queen's University, Kingston, Ontario, Canada. Electronic address: fverabadillo@ctg.queensu.ca.
Abstract
BACKGROUND: The epidermal growth factor receptor (EGFR) is a member of the ErbB family of membrane tyrosine-kinase receptors. Studies exploring the prognostic role of EGFR-overexpression in early breast cancer have shown variable results, and the true prognostic value of EGFR is unknown. METHODS: A systematic review of identified publications exploring the association between EGFR-overexpression (as defined from different techniques and cut-offs) and outcomes [disease-free (DFS) and, overall survival (OS)] in women with early breast cancer. The hazard ratios (HR) for DFS and OS were weighted and pooled in a meta-analysis using generic inverse variance and random effects modeling. RESULTS: Fifty-three studies comprising 21,418 women were included. EGFR-overexpression was found in 27% of the patients. Primary analysis included studies reporting HRs from multivariable analyses (10 studies including 4857 patients with HRs for OS and 17 studies comprising 8747 patients with HRs for DFS), EGFR-overexpression was associated with worse OS (HR 1.98, 95% CI: 1.59-2.47, p < .001) and DFS (HR 1.59, 95% CI 1.30-1.95, p < .001). The influence of EGFR overexpression on DFS was greater in women with triple negative tumors compared to women with non-triple negative tumors (HR 2.35 versus HR 1.45, respectively; p = .01). Analysis looking at odd ratios for both 5-year and 10-year for DFS and OS showed similar results. CONCLUSION: EGFR-overexpression appears to be associated with reduced OS and DFS in women with early breast cancer. Patients with triple negative and EGFR-overexpression have poorer OS and DFS than those with triple negative tumors and normal EGFR expression.
BACKGROUND: The epidermal growth factor receptor (EGFR) is a member of the ErbB family of membrane tyrosine-kinase receptors. Studies exploring the prognostic role of EGFR-overexpression in early breast cancer have shown variable results, and the true prognostic value of EGFR is unknown. METHODS: A systematic review of identified publications exploring the association between EGFR-overexpression (as defined from different techniques and cut-offs) and outcomes [disease-free (DFS) and, overall survival (OS)] in women with early breast cancer. The hazard ratios (HR) for DFS and OS were weighted and pooled in a meta-analysis using generic inverse variance and random effects modeling. RESULTS: Fifty-three studies comprising 21,418 women were included. EGFR-overexpression was found in 27% of the patients. Primary analysis included studies reporting HRs from multivariable analyses (10 studies including 4857 patients with HRs for OS and 17 studies comprising 8747 patients with HRs for DFS), EGFR-overexpression was associated with worse OS (HR 1.98, 95% CI: 1.59-2.47, p < .001) and DFS (HR 1.59, 95% CI 1.30-1.95, p < .001). The influence of EGFR overexpression on DFS was greater in women with triple negative tumors compared to women with non-triple negative tumors (HR 2.35 versus HR 1.45, respectively; p = .01). Analysis looking at odd ratios for both 5-year and 10-year for DFS and OS showed similar results. CONCLUSION:EGFR-overexpression appears to be associated with reduced OS and DFS in women with early breast cancer. Patients with triple negative and EGFR-overexpression have poorer OS and DFS than those with triple negative tumors and normal EGFR expression.
Authors: Moataz Reda; Worapol Ngamcherdtrakul; Shenda Gu; Daniel S Bejan; Natnaree Siriwon; Joe W Gray; Wassana Yantasee Journal: Cancer Lett Date: 2019-09-26 Impact factor: 8.679
Authors: Kyung-Ho Jung; Eun Jeong Lee; Jin Won Park; Jin Hee Lee; Seung Hwan Moon; Young Seok Cho; Kyung-Han Lee Journal: PLoS One Date: 2019-09-18 Impact factor: 3.240